Clinical Report: ACIP disruption leaves vaccine policy questions unresolved
Overview
At IDWeek 2026, speakers described unresolved vaccine-policy questions amid disruption to the Advisory Committee on Immunization Practices (ACIP). These included measles vaccination, seasonal respiratory vaccines, research needs and policies concerning Vaccines for Children coverage. Professional societies were providing guidance, but panelists emphasized that these efforts could not fully replace ACIP’s federal role.
Background
According to Rochelle Walensky, MD, MPH, ACIP was founded in 1964 and designated a federal advisory committee in 1972, formalizing requirements for transparency, public meetings and independent expert review.
Working groups review evidence and develop proposals. The committee publicly considers evidence using an evidence-to-recommendation framework, votes and submits recommendations to the CDC director. The framework addresses benefits and harms, public health importance, values, acceptability, resource use, equity and feasibility.
When adopted by CDC, ACIP recommendations influence immunization schedules, insurance coverage and the Vaccines for Children program. Walensky said ACIP was unable to meet under a court order at the time of the session.
Data Highlights
Item | Details reported |
|---|---|
ACIP history | Founded in 1964; designated a federal advisory committee in 1972 |
Vaccines for Children | ACIP has had authority to determine covered vaccines since 1993 |
Policy timeline described | Member changes in June 2025; childhood schedule overhaul in January 2026; court order blocking schedule and membership changes in March 2026; revised charter in June 2026 |
Research needs identified | RSV revaccination for adults older than 75; COVID-19 vaccination for health care personnel; an mRNA influenza vaccine for older adults |
Seasonal vaccine discussion | Dr. Walensky said CDC had not discussed seasonal respiratory vaccine recommendations since 2024 |
ACIP nominations | HHS was accepting nominations for new members through Dec. 31, 2026 |
Key Findings
Walensky said no policies were moving forward at the time of the session, including policies concerning Vaccines for Children coverage.
Unaddressed questions included broadening measles vaccination, updating seasonal respiratory vaccine recommendations and addressing research gaps.
The March court order arose from a lawsuit filed by IDSA and other organizations challenging newly selected members’ qualifications and appointment process, as well as recommendations the plaintiffs argued were inconsistent with scientific evidence.
Walensky described the June 2026 charter as narrowing ACIP’s vaccine recommendation role and emphasizing assessment of alternatives for disease prevention.
Jason Goldman, MD, MACP, characterized professional-society guidance as a necessary temporary response that could not replace a fully staffed, vetted and appropriately constituted ACIP.
IDSA encouraged eligible experts to apply or nominate colleagues and called for restoring ACIP’s established recommendation process with qualified, appropriately vetted members.
Clinical Implications
Demetre Daskalakis, MD, MPH, advised clinicians to verify CDC webpage updates through other sources. Walensky emphasized transparency about supporting evidence, citing the Vaccine Integrity Project’s publication of search protocols and information about its evidence reviews.
For patient conversations, Goldman recommended listening to identify the concern behind a question, explaining the data supporting a recommendation and encouraging scrutiny of information sources. He emphasized earning patients’ trust while welcoming questions.
These recommendations addressed evaluating and communicating guidance; the article did not provide vaccine dosing schedules or individual treatment protocols.
Conclusion
The session described unresolved federal vaccine-policy work and the limitations of professional societies’ interim response. Panelists emphasized transparent evidence review, verification of information and clear patient communication. IDSA called for restoring ACIP’s established vaccine recommendation process.
Related Resources & Content
ACIP disruption leaves vaccine policy questions unresolved — Olivia Anderson — IDSA Reporter — November 10, 2026 — Source article.
Opportunities in Vaccine Advocacy and Communication: How to Work Together in Today’s World — Rochelle Walensky, Jason Goldman and Demetre Daskalakis, panelists — IDWeek 2026 — October 22, 2026 — Official session listing. idweek2026.eventscribe.net
Respiratory Season Virus Vaccines: Restoring Confidence and Trust — Fryhofer SA, Garcia AM, Osterholm MT, Walensky RP — JAMA — Published online September 2, 2026 — https://doi.org/10.1001/jama.2026.18338. jamanetwork.com
COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season — Lipson RA, Senerth E, Watson MA, et al — JAMA — Published online September 2, 2026 — https://doi.org/10.1001/jama.2026.18191. jamanetwork.com
RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season — Senerth E, Sheikholeslamian SM, Babatunde I, et al — JAMA — Published online September 2, 2026 — https://doi.org/10.1001/jama.2026.17871. jamanetwork.com
Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season — Senerth E, Sheikholeslamian SM, Sivakumaran K, et al — JAMA — Published online September 2, 2026 — https://doi.org/10.1001/jama.2026.18126.
Based on findings from:
ACIP disruption leaves vaccine policy questions unresolved
Olivia Anderson. Idsa Reporter, 2026.
https://idsareporter.com/issues/2026/november-2026/acip-disruption-leaves-vaccine-policy-questions-unresolved/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.